FindTrial
Sign In

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-95597528 for the Treatment of Adult Participants with Moderate to Severe Atopic Dermatitis

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-523464-20-00
Enrollment
7
Registered
2026-05-19
Start date
Unknown
Completion date
Unknown
Last updated
2026-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate to Severe Atopic Dermatitis

Brief summary

EASI 75 at Week 12

Interventions

DRUGPlacebo for JNJ-95597528
DRUGJNJ-95597528

Sponsors

Janssen Cilag International
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
EASI 75 at Week 12—

Outcome results

None listed

Source: EU CTIS · Data processed: May 20, 2026